Palisade Bio

Palisade Bio, Inc. is a biopharmaceutical company, which engages in the development of oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. It offers LB1148, an oral formulation of a broad-spectrum serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery. The company was founded on September 6, 2011 and is headquartered in Carlsbad, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Commenced enrollment and dosing in Phase 1 clinical study of PALI-2108 for the treatment of moderate-to-severe Ulcerative Colitis (UC)

Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108

Targeted, better-tolerated oral PDE4 inhibitors are an unmet need in inflammatory bowel disease (IBD) PALI-2108 demonstrates in ex vivo studies; targeted activation and reduced side effects, potentially enhancing patient compliance compared to existing PDE4 inhibitors Data presented at the American College of Gastroenterology's (ACG) 2024 Annual Scientific Meeting Carlsbad, CA, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a biopharmaceutical company dedicated to developing novel therapeutics for patients with autoimmune, inflammatory, and fibrotic diseases has announced the presentation of data from two translational studies demonstrating the ex vivo bioactivation of PALI-2108 in stool samples and whole blood. This orally administered, colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug is in development for patients with ulcerative colitis (UC).

Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis

– Company has received a No Objection Letter from Health Canada in response to submission of its Phase 1 Clinical Trial Application (CTA)

Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC)

– Continued progress toward commencement of Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC) before year end

Palisade Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

– Phase 1 human clinical study of PALI-2108 for the treatment of Ulcerative Colitis (UC) on track to commence before year end

Palisade Bio Selects Dose for Upcoming Phase 1 Clinical Study of PALI-2108 for Ulcerative Colitis

Mitch Jones, MD, PhD, CMO of Palisade Bio highlights recent findings from a microbiome study confirming local bioactivation of lead product candidate, PALI-2108

Palisade Bio Participates in Virtual Investor “What this Means” Segment

Findings demonstrate that the microbiome and enzymes are sufficient in mouse, dog, and Normal Healthy Volunteers (NHV) and Ulcerative Colitis (UC) patients

Palisade Bio Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Lead Product Candidate, PALI-2108

Patent includes Composition of Matter claims for both PALI-2108 and PALI-1908 programs Patent includes broad claims for “Gut Microbiota Bioactivated PDE4 Inhibitor Precursors” with similar structure to PALI-2108 and PALI-1908 This patent family provides Composition of Matter coverage beyond 2042 PALI-2108 is in development to treat patients with active moderate-to-severely active Ulcerative Colitis (UC) PALI-1908 is in development to treat patients with active fibro stenotic Crohn's Disease (CD) Carlsbad, CA, July 19, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.  (Nasdaq: PALI) (the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that European Patent Office (EPO) has issued a decision to grant notice for patent number 4,157,853 titled, “Gut Microbiota Bioactivated PDE4 Inhibitor Precursors.” Based on the intention to grant notice, the Company expects the EPO to issue a patent July 31, 2024.

Palisade Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent for Lead Product Candidate, PALI-2108

Company has now completed murine and non-murine pivotal nonclinical studies using GMP PALI-2108 drug substance Company has successfully formulated enteric-coated tablets of PALI-2108 and has demonstrated consistent and reliable drug release profiles Company on track to commence Phase 1 human clinical study of PALI-2108 for the treatment of moderate-to-severe ulcerative colitis (UC) before year end Carlsbad, CA, July 11, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.  (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced the successful completion of the first Good Manufacturing Practice (GMP) batch of its drug substance PALI-2108, an orally administered, locally acting colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug in development for patients affected by UC. The GMP manufacturing was conducted in partnership with Eurofins, a contract development and manufacturing organization.

Palisade Bio Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product

Live video webcast on Wednesday, June 26 th at 4:00 PM ET Carlsbad, CA, June 24, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it will participate in the Virtual Investor Closing Bell Series on Wednesday, June 26, 2024 at 4:00 PM ET. As part of the event, J.D.

Palisade Bio to Participate in the Virtual Investor Closing Bell Series

– Collaboration advancing Palisade Bio's precision medicine approach through access to cutting-edge expertise and tools in bioinformatics

Palisade Bio Provides Update on Advancement of its Strategic Collaboration with Strand Life Sciences

Palisade Bio (PALI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Bears are Losing Control Over Palisade Bio (PALI), Here's Why It's a 'Buy' Now

PALI-2108 is orally delivered and colon-specific allowing for local activity with low systemic exposure Company on track to commence Phase 1 human clinical study of PALI-2108 for the treatment of UC before year end Carlsbad, CA, June 11, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.  (Nasdaq: PALI) (“Palisade” or the “Company”), biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that the Canadian Intellectual Property Office (CIPO) has issued a Notice of Allowance for patent application number 3,174,137 titled, “Gut Microbiota Bioactivated PDE4 Inhibitor Precursors.” This patent covers the composition of PALI-2108, the Company's orally administered, locally acting colon-specific Phosphodiesterase-4 (PDE4) inhibitor prodrug in development for patients affected by Ulcerative Colitis (UC).

Palisade Bio Announces Notice of Allowance for Canadian Patent Covering Lead Product Candidate, PALI-2108

Live video webcast on Monday, June 17 th at 12:00 PM ET Carlsbad, CA, June 10, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it will present at the Virtual Investor Pitch Conference on June 17, 2024 at 12:00 PM ET. As part of the event, J.D.

Palisade Bio to Present at the Virtual Investor Pitch Conference

Data presented at Digestive Disease Week (DDW) 2024 Preclinical data demonstrate PALI-2108 to be safe, effective, and well tolerated PALI-2108 is orally delivered and colon-specific allowing for local activity with low systemic exposure PALI-2108 exhibited a dose-dependent efficacy response in two DSS colitis mouse models, achieving efficacy comparable to doses of apremilast considered intolerable for human use in Ulcerative Colitis (UC) patients Company on track to commence Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of UC before year end Carlsbad, CA, May 21, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced the presentation of positive preclinical data from PALI-2108, an orally administered, locally acting colon-specific Phosphodiesterase-4 (PDE4) inhibitor prodrug in development for patients affected by UC, at DDW 2024 being held in Washington, D.C., May 18-21, 2024.

Palisade Bio's Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse Models

– Company on track to commence Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC) before year end

Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update

Wall Street and biotech industry veteran with expertise across corporate finance, business development, M&A, licensing, and strategic alliance transactions, globally

Palisade Bio Appoints Margery Fischbein to its Board of Directors

Carlsbad, CA, May 07, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.  (Nasdaq: PALI), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, is announcing today that it has closed its previously announced private placement with an institutional investor for the purchase of 615,242 shares of common stock (or certain pre-funded warrants in lieu thereof) for gross proceeds of approximately $4 million, before deducting placement agent fees and other offering expenses payable by the Company.

Palisade Bio Announces Closing of $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules

Carlsbad, CA, May 02, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.  (Nasdaq: PALI), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, is announcing today that it has entered into a definitive agreement with an institutional investor for the purchase of 615,242 shares of common stock (or certain pre-funded warrants in lieu thereof) in a private placement at a purchase price per share of $6.5015, priced at-the-market under Nasdaq rules. The Company expects to receive gross proceeds of approximately $4 million, before deducting placement agent fees and other offering expenses payable by the Company.

Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules

Company on track to commence Phase 1 human clinical study of PALI-2108 for the treatment of Ulcerative Colitis (UC) before year end

Palisade Bio's Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS)

Palisade Bio Inc (NASDAQ: PALI) opened roughly 50% up on Tuesday after teaming up with Strand Life Sciences.  Here's what it means for Palisade Bio stock The strategic collaboration puts its patient datasets together with bioinformatics tools of the genomics software and services company.

Palisade Bio stock rallies on Strand Life Sciences partnership

– Collaboration grants Palisade Bio access to cutting-edge expertise and tools in bioinformatics – Partnership marks a significant value-driving milestone in Palisade Bio's mission to redefine UC treatment through targeted interventions based on PDE4-related biomarkers Carlsbad, CA, April 23, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.  (Nasdaq: PALI) (“Palisade”, “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced it has entered into a transformative strategic collaboration with Strand Life Sciences, a leading bioinformatics specialist, aimed at advancing precision medicine for ulcerative colitis (UC) therapy. The collaboration with Strand Life Sciences provides Palisade Bio access to advanced bioinformatics tools vital for understanding complex disease pathways and predicting responses to PDE4 inhibitors.

Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach

Palisade Bio (NASDAQ: PALI ) stock is climbing higher on Tuesday after the clinical-stage biopharmaceutical company revealed additional data for its ulcerative colitis (UC) treatment. The big news here is Palisade Bio completing its analysis of ex-vivo bioactivation of PALI-2108.

Why Is Palisade Bio (PALI) Stock Up 57% Today?

Company continues advancing ongoing development of targeted therapies for ulcerative colitis (UC) Carlsbad, CA, April 16, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.  (Nasdaq: PALI) (“Palisade”, “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, announced today the successful completion of its analysis evaluating ex-vivo bioactivation of PALI-2108, an orally administered, locally acting colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug in development for patients affected by UC. These findings demonstrated that PALI-2108 exhibited efficient ex-vivo conversion into its active PDE4 inhibitor form in stool samples from both normal healthy volunteers and patients with UC.

Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients' Stool

– Live webcast with members of Palisade Bio management on Tuesday, April 16 th at 12:00 PM ET

News for Palisade Bio Stock (PALI)